AGREEMENT ---------Registration Rights Agreement • November 5th, 2004 • Provectus Pharmaceuticals Inc • Pharmaceutical preparations • Tennessee
Agreement ---------Consulting Agreement • October 1st, 2003 • Provectus Pharmaceuticals Inc • Pharmaceutical preparations
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT ----------------------------- THIS SECURITIES PURCHASE AGREEMENT (this "Agreement") dated as of July 28, 2004, by and among PROVECTUS PHARMACEUTICALS, INC., a Nevada corporation (the "Company"), and the...Escrow Agreement • October 7th, 2004 • Provectus Pharmaceuticals Inc • Pharmaceutical preparations • New Jersey
Exhibit 4.3 NEITHER THE OFFER NOR THE SALE OF THIS WARRANT OR THE SHARES ISSUABLE UPON THE EXERCISE OF THIS WARRANT HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"). EXCEPT AS OTHERWISE SET FORTH HEREIN OR IN A SECURITIES...Provectus Pharmaceuticals Inc • May 16th, 2005 • Pharmaceutical preparations • New York
EXHIBIT 4.1 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT, dated as of _______, 2005, is entered into by and between PROVECTUS PHARMACEUTICALS, INC., a Nevada corporation, with headquarters located at 7327 Oak Ridge Highway, Suite...Securities Purchase Agreement • August 30th, 2005 • Provectus Pharmaceuticals Inc • Pharmaceutical preparations • New York
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • February 28th, 2013 • Provectus Pharmaceuticals Inc • Pharmaceutical preparations
This Registration Rights Agreement (this “Agreement”) is made and entered into as of February 22, 2013, between Provectus Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”).
AGREEMENT ---------Settlement Agreement • June 26th, 2003 • Provectus Pharmaceuticals Inc • Pharmaceutical preparations
Exhibit 4.1 NEITHER THE OFFER NOR THE SALE OF THIS DEBENTURE OR THE SHARES ISSUABLE UPON THE CONVERSION OF THIS DEBENTURE HAS BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"). EXCEPT AS OTHERWISE SET FORTH HEREIN OR IN A...Provectus Pharmaceuticals Inc • May 16th, 2005 • Pharmaceutical preparations • New York
WARRANTProvectus Pharmaceuticals Inc • October 7th, 2004 • Pharmaceutical preparations
EXHIBIT 4.11 WARRANTProvectus Pharmaceuticals Inc • May 16th, 2005 • Pharmaceutical preparations
Exhibit 4.9 CONSULTING AGREEMENT This CONSULTING AGREEMENT is entered into by Provectus Pharmaceuticals, Inc., ("PVCT") an OTC BB NASD regulated public Company; and Dr. Phillip C. Baker (the "Consultant"), effective this 5th day of November, 2003....Consulting Agreement • November 10th, 2004 • Provectus Pharmaceuticals Inc • Pharmaceutical preparations
EXHIBIT 99.1 SUPPLY AGREEMENT This Supply Agreement ("Agreement") is made as of the 1st day of June, 2004 by and between AmericsourceBergen Drug Corporation ("AmerisourceBergen") with an address at 1300 Morris Drive, Chesterbrook, PA 19087-5594 and...Supply Agreement • November 12th, 2004 • Provectus Pharmaceuticals Inc • Pharmaceutical preparations • Pennsylvania
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT Securities Purchase Agreement (this "Agreement"), dated as of March 30, 2005, by and among Provectus Pharmaceuticals, Inc., a Nevada corporation, with headquarters located at 7327 Oak Ridge Highway, Suite A,...Securities Purchase Agreement • May 16th, 2005 • Provectus Pharmaceuticals Inc • Pharmaceutical preparations • New York
INDEMNIFICATION AGREEMENTIndemnification Agreement • July 16th, 2020 • Provectus Biopharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of July 20, 2020, between PROVECTUS Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), and Webster Bailey (“Indemnitee”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • August 25th, 2016 • Provectus Biopharmaceuticals, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of August 25, 2016, between Provectus Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
Exhibit 4.2 THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE AND MAY NOT BE SOLD OR OFFERED FOR SALE IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES OR...Provectus Pharmaceuticals Inc • January 16th, 2004 • Pharmaceutical preparations
EXHIBIT 10.21 THIS NOTE AND THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 (THE "ACT") OR ANY APPLICABLE STATE SECURITIES LAWS. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE...Provectus Pharmaceuticals Inc • March 31st, 2005 • Pharmaceutical preparations
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • December 23rd, 2010 • Provectus Pharmaceuticals Inc • Pharmaceutical preparations • Nevada
REGISTRATION RIGHTS AGREEMENT (this "Agreement"), dated as of December 22, 2010, by and between PROVECTUS PHARMACEUTICALS, INC., a Nevada corporation, (the "Company"), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (together with it permitted assigns, the “Buyer”). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Purchase Agreement by and between the parties hereto, dated as of the date hereof (as amended, restated, supplemented or otherwise modified from time to time, the "Purchase Agreement").
PROVECTUS BIOPHARMACEUTICALS, INC. Up to $50,000,000 of Shares of Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales AgreementProvectus Biopharmaceuticals, Inc. • April 30th, 2014 • Pharmaceutical preparations • New York
Provectus Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follows:
WARRANTProvectus Pharmaceuticals Inc • August 30th, 2005 • Pharmaceutical preparations
Buyer Address and Facsimile Number Number of Common Shares Number of Series A Warrant Shares Number of Series B Warrant Shares Number of Series C Warrant Shares Purchase Price Legal Representative’s Address and Facsimile Number Cranshire Capital, L.P....Securities Purchase Agreement • January 13th, 2011 • Provectus Pharmaceuticals Inc • Pharmaceutical preparations • New York
EXHIBIT 4.15 December 8, 2004 Venture Catalyst, LLC Re: Consulting Agreement -------------------- Dear Venture Catalyst, LLC: This letter sets forth our agreement ("AGREEMENT") with respect to Venture Catalyst, LLC ("VC"), providing consulting...Provectus Pharmaceuticals Inc • June 14th, 2005 • Pharmaceutical preparations • Tennessee
The following is a statement of the rights of Lender under this Note and the conditions to which this Note and the Borrower are subject, and to which the Borrower hereby agrees: 1Provectus Pharmaceuticals Inc • May 16th, 2005 • Pharmaceutical preparations
RecitalsConsulting Agreement • September 17th, 2002 • Provectus Pharmaceuticals Inc • Special industry machinery, nec
EXHIBIT 4.13 WARRANTProvectus Pharmaceuticals Inc • May 16th, 2005 • Pharmaceutical preparations
Exhibit 4.2 INVESTOR REGISTRATION RIGHTS AGREEMENT -------------------------------------- THIS REGISTRATION RIGHTS AGREEMENT (this "Agreement") dated as of July 28, 2004, by and among PROVECTUS PHARMACEUTICALS, INC., a Nevada corporation (the...Investor Registration Rights Agreement • October 7th, 2004 • Provectus Pharmaceuticals Inc • Pharmaceutical preparations • New Jersey
COMMON STOCK PURCHASE WARRANT PROVECTUS PHARMACEUTICALS, INC.Common Stock Purchase • December 23rd, 2010 • Provectus Pharmaceuticals Inc • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, Lincoln Park Capital Fund, LLC (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after __________, 2010 (the “Initial Exercise Date”) and on or prior to the close of business on the fifth anniversary of the date hereof (the “Termination Date”) but not thereafter, to subscribe for and purchase from Provectus Pharmaceuticals, Inc., a Nevada corporation (the “Company”), up to 500,000 shares (the “Warrant Shares”) of Common Stock The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
Exhibit 10.2 STANDBY EQUITY DISTRIBUTION AGREEMENT ------------------------------------- THIS STANDBY EQUITY DISTRIBUTION AGREEMENT (the "Agreement") dated as of July 28, 2004 by and between CORNELL CAPITAL PARTNERS, LP, a Delaware limited partnership...Equity Distribution Agreement • November 10th, 2004 • Provectus Pharmaceuticals Inc • Pharmaceutical preparations • New Jersey
Exhibit 4.4 REGISTRATION RIGHTS AGREEMENT Registration Rights Agreement (this "Agreement"), dated as of March 30, 2005, by and among Provectus Pharmaceuticals, Inc., a Nevada corporation, (the "Company") and each of the undersigned (the "Initial...Registration Rights Agreement • May 16th, 2005 • Provectus Pharmaceuticals Inc • Pharmaceutical preparations • New York
PROVECTUS BIOPHARMACEUTICALS, INC. DEALER-MANAGER AGREEMENT January 30, 2017Dealer-Manager Agreement • February 3rd, 2017 • Provectus Biopharmaceuticals, Inc. • Pharmaceutical preparations • New York
The following (this “Agreement”) will confirm our agreement relating to the proposed rights offering (the “Rights Offering”) to be undertaken by Provectus Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), pursuant to which the Company will distribute to holders of record of its common stock, par value $0.001 per share (the “Common Stock”), and holders of the Company’s class of warrants with an exercise price of $0.85 per share expiring June 19, 2020 (“Listed Warrants”) subscription rights (the “Rights”) to purchase up to an aggregate of 19,662,782 units (the “Units”), each Unit consisting of four shares of Common Stock (the “Rights Shares”) and one-half share of Series C Convertible Preferred Stock (the “Preferred Stock”), at a subscription price of $1.00 per Unit in cash (the “Subscription Price”). The Subscription Price is subject to decrease by up to 20% by the Company after consultation with the Dealer-Manager, as described in the Prospectus (as defined herein).
EXHIBIT 4.10 FINANCIAL ADVISORY AND INVESTMENT BANKING AGREEMENT This Agreement is made and entered into as of the 15th day of August 2004 (the "Effective Date") between Network 1 Financial Securities ("Network 1" or the "Consultant") and Provectus...Investment Banking Agreement • May 16th, 2005 • Provectus Pharmaceuticals Inc • Pharmaceutical preparations • New York
FORM OF SERIES C WARRANT] PROVECTUS PHARMACEUTICALS, INC. Warrant To Purchase Common StockProvectus Pharmaceuticals Inc • January 13th, 2011 • Pharmaceutical preparations • New York
Provectus Pharmaceuticals, Inc., a Nevada corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [CRANSHIRE CAPITAL, L.P.], [OTHER BUYERS], the registered holder hereof or its permitted assigns (the “Holder”), is entitled, subject to the terms set forth below, to purchase from the Company, at the Exercise Price (as defined below) then in effect, upon exercise of this Warrant to Purchase Common Stock (including any Warrants to Purchase Common Stock issued in exchange, transfer or replacement hereof, the “Warrant”), at any time or times on or after the Issuance Date, but not after 11:59 p.m., New York time, on the Expiration Date (as defined below), [______________]1 (subject to adjustment as provided herein) fully paid and non-assessable shares of Common Stock (as defined below) (the “Warrant Shares”). Except as otherwise defined herein, capitalized terms in this Warrant shall have the meanin
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 13th, 2014 • Provectus Biopharmaceuticals, Inc. • Pharmaceutical preparations • Tennessee
THIS AGREEMENT made as of this 1st day of July 2013 by and between PROVECTUS PHARMACEUTICALS, INC., a Nevada Corporation with its principal place of business in Knoxville, Tennessee (the “Company”), and Timothy C. Scott, Ph.D. (the “Executive”).
RECITALSReaffirmation Agreement • May 16th, 2005 • Provectus Pharmaceuticals Inc • Pharmaceutical preparations
ContractSecurities Purchase Agreement • March 12th, 2010 • Provectus Pharmaceuticals Inc • Pharmaceutical preparations • New York